Did you know 2024 - Pharma Machines & Technology

DID YOU KNOW?

Approximately 1,200 pharmaceutical companies had active R&D pipelines, and this number increased to over 6,100 by January 2024.
Global medicine use rose by 414 billion doses in the past five years and is projected to increase by another 400 billion by 2028
The government has expanded a committee to reform drug and medical device pricing, including civil rights activists, to evaluate essential medicine availability and incentivize industry growth.
The Serum Institute of India shipped the first batch of R21/Matrix-M malaria vaccine to Africa, dispatching 43,200 doses. A total of 163,800 doses are allocated for the Central African Region, with other African nations to follow.
The domestic pharmaceutical formulations market is projected to be worth Rs 5.5 trillion by 2034, growing at a compound annual growth rate (CAGR) of 10 percent.
Emerging markets such as Latin America, Africa, Russia, the CIS, and Southeast Asia are growing 1.5 to 2 times faster than regulated markets, attracting Indian pharmaceutical giants.
The Indian pharmaceutical industry has been experiencing double-digit growth year on year, achieving this level of growth in real terms over the past decade.
The government is contemplating a ban on producing, importing, and distributing chloramphenicol and nitrofurans antibiotics in food-producing animal-rearing systems because they are misused in poultry and animal feed supplements.
A study conducted in the United States revealed that 50 percent of all generic drugs and 40 percent of all prescription medicines are sourced from India.
According to a drug alert issued by the CDSCO, a total of 52 samples failed the quality test in June
The government has allowed global tenders to be floated for the procurement of 120 drugs, including the anti-diabetic medication Semaglutide after a lack of domestic options.
In May 2024, the Indian pharmaceutical market grew by 5.2%, driven by double-digit value growth in anti-infectives (12%) and respiratory therapies (10.2%) due to sudden weather changes.
Out of over 300,000 clinical trials, only 5-10% of eligible patients are aware of these studies.
Nineteen percent of trials prematurely close or terminate due to insufficient participant enrollment, resulting in an estimated loss of value amounting to $800 billion.